2015-05-28 13:53:46 UTC

FDA Approves New IBS-D Therapies

May 28, 2015

Two new treatments have received FDA approval to treat adults with diarrhea-predominant IBS.

The FDA has approved two new treatments for IBS with diarrhea in adult men and women — Viberzi (eluxadoline) and Xifaxan (rifaximin). The products are manufactured by two different companies.

Viberzi, which contains a new active ingredient, is taken orally twice daily with food. Viberzi activates receptors in the nervous system that can lessen bowel contractions. Viberzi is intended to treat adults with IBS-D.

Xifaxan can be taken orally three times a day for 14 days, for the treatment of abdominal pain and diarrhea in patients with IBS-D. Patients who experience a recurrence of symptoms can be retreated with a 14-day treatment course, up to two times. Xifaxan, an antibiotic derived from rifampin, was previously approved as treatment for travelers’ diarrhea caused-by E. coli and for reducing the risk of recurring overt hepatic encephalopathy, the changes in brain function that occur when the liver is unable to remove toxins from the blood. The exact mechanism of action of Xifaxan for treatment of IBS-D is not known, but is thought to be related to changes in the bacterial content of the gastrointestinal tract.

More on Irritable Bowel Syndrome

2018 Research Grants Open for Applications

Dec. 11, 2017

Don't lose sight of award deadlines during the busy holiday season. Read on to discover open grants from the AGA Research Foundation and when applications are due.

Grant Spotlight: AGA Pilot Awards

Nov. 8, 2017

Take your new research project idea and make it a reality with an AGA research award. Eight grants are open with a Jan. 12, 2018, deadline.

The Lowdown on the Low-FODMAP Diet

Nov. 1, 2017

As the low-FODMAP diet grows in popularity, know the facts to help answer patient questions and provide guidance.